Eurofins Scientific shares are consolidating this Monday, February 9, 2026, midday, dropping 1.12% to €67.24. The analytical and certification genius's stock thus gives up some of the gains accumulated in recent weeks, after a year-over-year increase of 31.84%. This adjustment phase occurs as the stock trades above its structuring moving averages.
The graphical analysis of Eurofins Scientific reveals an intermediate positioning of the price, which remains above its 50-day moving average set at €64.58, as well as its 200-session average at €62.07. This configuration remains generally favorable, although the stock is distant from its 20-day moving average set at €70.22. Regarding oscillators, the relative strength index is at 36 points, indicating a short-term bearish trend without reaching an extreme oversold zone. This reading is in a context of monthly volatility measured at 9.21%, reflecting moderate fluctuations for this specialist in analytical testing and laboratory services.
Recent Performance Context
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The decline observed this Monday follows a notable bullish sequence, with a quarterly increase of 15.37% and an advance of more than 31% over twelve months. This performance reflects a renewed interest from investors in the Luxembourg-based global leader in bioanalysis, which has faced operational challenges in some divisions in recent years. The current valuation places the stock in an intermediate zone between its technical support identified at €61.62 and resistance at €73.12. Thus, today's corrective movement appears more as a breathing phase rather than a major reversal, with the price remaining well above its previous lows. The group's trajectory will largely depend on its ability to maintain organic growth and consolidate margins in a demanding competitive environment.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
